Hemophagocytic syndrome is a highly lethal disease with a potential cure, which should be determined by the patient’s condition, tolerance to treatment, and primary disease.
Hemophagocytic syndrome is a severe inflammatory response syndrome caused by abnormalities in hereditary or acquired immunoregulatory function. It is a rapidly progressive and highly fatal disease that can be divided into primary and secondary, with secondary being secondary to multiple factors such as tumors, rheumatologic and immune diseases, and infections.
The treatment of phagocytic syndrome begins with controlling the excessive inflammatory response, followed by consideration of the treatment of the primary disease, which, although difficult, still holds promise for cure.
If the primary disease is a serious infection, a cure can be achieved when the infection is controlled; however, if the primary disease is a malignant tumor, a cure is more difficult, but survival can be prolonged by active treatment, such as cytarabine chemotherapy for acute myeloid leukemia.
If hemophagocytic syndrome occurs, it is necessary to actively consult the doctor and follow the doctor’s instructions for reasonable treatment.